- Previous Close
3.0400 - Open
3.0200 - Bid 2.9600 x --
- Ask 3.0600 x --
- Day's Range
2.8800 - 3.0200 - 52 Week Range
2.8800 - 24.1000 - Volume
0 - Avg. Volume
3 - Market Cap (intraday)
111.774M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-6.0000 - Earnings Date Mar 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
bioagelabs.com62
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: Y7G.DU
View MorePerformance Overview: Y7G.DU
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: Y7G.DU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: Y7G.DU
View MoreValuation Measures
Market Cap
106.81M
Enterprise Value
-206.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.44%
Return on Equity (ttm)
-50.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-71.11M
Diluted EPS (ttm)
-6.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
354.35M
Total Debt/Equity (mrq)
2.69%
Levered Free Cash Flow (ttm)
-34.21M